KR102863894B1 - Gpr35 조절제 - Google Patents

Gpr35 조절제

Info

Publication number
KR102863894B1
KR102863894B1 KR1020217026911A KR20217026911A KR102863894B1 KR 102863894 B1 KR102863894 B1 KR 102863894B1 KR 1020217026911 A KR1020217026911 A KR 1020217026911A KR 20217026911 A KR20217026911 A KR 20217026911A KR 102863894 B1 KR102863894 B1 KR 102863894B1
Authority
KR
South Korea
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217026911A
Other languages
English (en)
Korean (ko)
Other versions
KR20210119485A (ko
Inventor
로버트 히구치
Original Assignee
프로메테우스 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로메테우스 바이오사이언시즈, 인크. filed Critical 프로메테우스 바이오사이언시즈, 인크.
Publication of KR20210119485A publication Critical patent/KR20210119485A/ko
Application granted granted Critical
Publication of KR102863894B1 publication Critical patent/KR102863894B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020217026911A 2019-01-24 2020-01-23 Gpr35 조절제 Active KR102863894B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962796459P 2019-01-24 2019-01-24
US62/796,459 2019-01-24
US201962873703P 2019-07-12 2019-07-12
US62/873,703 2019-07-12
US201962928223P 2019-10-30 2019-10-30
US62/928,223 2019-10-30
PCT/US2020/014777 WO2020154492A1 (en) 2019-01-24 2020-01-23 Gpr35 modulators

Publications (2)

Publication Number Publication Date
KR20210119485A KR20210119485A (ko) 2021-10-05
KR102863894B1 true KR102863894B1 (ko) 2025-09-23

Family

ID=71733100

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026911A Active KR102863894B1 (ko) 2019-01-24 2020-01-23 Gpr35 조절제

Country Status (13)

Country Link
US (2) US11053251B2 (https=)
EP (1) EP3914256B1 (https=)
JP (1) JP7588077B2 (https=)
KR (1) KR102863894B1 (https=)
CN (1) CN113631168B (https=)
AU (1) AU2020210930B2 (https=)
BR (1) BR112021014566A2 (https=)
CA (1) CA3127786A1 (https=)
IL (1) IL285074B2 (https=)
MA (1) MA54825A (https=)
MX (1) MX2021008941A (https=)
TW (1) TWI845600B (https=)
WO (1) WO2020154492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
EP4185379A4 (en) * 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
GB202303387D0 (en) * 2023-03-08 2023-04-19 Thirtyfivebio Ltd Compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119252A2 (en) * 2004-05-26 2005-12-15 Arena Pharmaceuticals, Inc. Modulators of gpr35 for the treatment of metabolic-related disorders
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
GB1421970A (en) * 1973-06-12 1976-01-21 May & Baker Ltd 8-azapurin-6-one derivatives
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
WO2005085867A2 (en) * 2004-02-27 2005-09-15 Pfizer Japan, Inc. Screening method for emulators of neural activity and digestive system using gpr35
US20070287630A1 (en) 2006-06-12 2007-12-13 Driwater, Inc. Moisturizing agent with nutrients
WO2012167053A1 (en) * 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
SG11201600853UA (en) 2013-08-05 2016-03-30 Twist Bioscience Corp De novo synthesized gene libraries
US20150273088A1 (en) * 2014-03-28 2015-10-01 Washington University Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto
KR102481020B1 (ko) 2014-06-29 2022-12-26 프로파일 프러덕츠 엘엘씨 나무껍질 및 목재 섬유 성장 배지
WO2018195328A1 (en) * 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
EP3920953A4 (en) 2019-02-08 2022-12-14 Cedars-Sinai Medical Center METHODS, SYSTEMS AND KITS FOR THE TREATMENT OF INFLAMMATORY DISEASES TARGETED FOR IL18R1
WO2020163713A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CA3162905A1 (en) 2019-11-27 2021-06-03 Cedars-Sinai Medical Center Predicting extraintestinal manifestations of inflammatory bowel disease
EP4185379A4 (en) 2020-07-23 2023-11-22 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35
AU2021377688A1 (en) 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035584A1 (fr) 2002-10-16 2004-04-29 Universite Louis Pasteur Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Pharmacology and Experimental Therpeutics, 2012, Vol. 343, pp. 683-695.

Also Published As

Publication number Publication date
US20210380590A1 (en) 2021-12-09
CA3127786A1 (en) 2020-07-30
CN113631168A (zh) 2021-11-09
CN113631168B (zh) 2024-11-19
MX2021008941A (es) 2021-10-13
EP3914256B1 (en) 2024-05-29
WO2020154492A1 (en) 2020-07-30
US20200239476A1 (en) 2020-07-30
KR20210119485A (ko) 2021-10-05
US11773101B2 (en) 2023-10-03
IL285074A (en) 2021-09-30
MA54825A (fr) 2021-12-01
IL285074B1 (en) 2024-08-01
EP3914256A4 (en) 2022-09-28
AU2020210930B2 (en) 2025-08-14
JP7588077B2 (ja) 2024-11-21
EP3914256A1 (en) 2021-12-01
IL285074B2 (en) 2024-12-01
TW202043234A (zh) 2020-12-01
TWI845600B (zh) 2024-06-21
BR112021014566A2 (pt) 2022-01-04
JP2022518523A (ja) 2022-03-15
AU2020210930A1 (en) 2021-09-09
US11053251B2 (en) 2021-07-06

Similar Documents

Publication Publication Date Title
KR102863894B1 (ko) Gpr35 조절제
US11884680B2 (en) Bromodomain inhibitors
EP3027616B1 (en) Azaindole compounds as modulators of rorc
CA2890981A1 (en) Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
AU2022253683A1 (en) Deuterated dhodh inhibitors
TW202332436A (zh) 治療用化合物
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
JP2022549435A (ja) Ｊａｋ阻害剤
US20230151017A1 (en) Therapeutic agents targeting gpr35
JPWO2019235553A1 (ja) アゼチジン誘導体及びそのプロドラッグ
EA048936B1 (ru) Модуляторы gpr35
WO2025064325A1 (en) Gpr35 modulators
HK40059523A (en) Gpr35 modulators
HK40097518A (zh) 氘化的dhodh抑制剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)